A research study offering treatment for people who have obsessive-compulsive disorder (OCD) and are currently taking one of the following medications and still have unwanted symptoms:

  • Clomipramine (Anafranil)
  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)

The goal of the study is to understand whether patients with OCD on serotonin reuptake inhibitors (SRIs) who achieve wellness from EX/RP can safely discontinue their medication.

Eligible participants initially remain on a stable dose of their OCD medication and will receive cognitive-behavioral therapy (CBT) consisting of exposure and ritual prevention (EX/RP) twice a week for up to 12 weeks as additional treatment. 

Participants who become well (minimal-to-mild OCD symptoms) after the EX/RP will be randomly assigned to either continue their medication or begin to taper off their medication and have it gradually replaced with a placebo. 

All patients will be carefully monitored throughout the study for 24 weeks. No one who has not become well after 12 weeks of EX/RP will discontinue their medication. Individuals who do not improve significantly will be referred elsewhere to receive appropriate clinical treatment.

Organization
University of Pennsylvania
Principal Investigator
Edna Foa, PhD
Eligibility Criteria

You may be eligible if

  • You have OCD.
  • You are between the ages of 18 and 75.
  • You are still having bothersome symptoms while taking one of the medications listed below for OCD.
  • You are interested in receiving no-cost therapy treatment that may improve your symptoms so that you may be able to stop taking your medication.
  • Clomipramine (Anafranil)
  • Fluoxetine (Prozac)
  • Fluvoxamine (Luvox)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)
Contact
215-746-3327
Location
3535 Market Street, Philadelphia, PA 19104
State
PA